All In Biotech

Drug Trial Radar · NCT07138209

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 3 Randomized Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

228

Planned (sponsor's estimate)

Start

Nov 7, 2025

Primary completion

Dec 2027

Study completion Dec 2029

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.

Conditions

  • Relapsed or Refractory Multiple Myeloma

Interventions

  • QLS32015Drug

    QLS32015 will be administered subcutaneously.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

  • SelinexorDrug

    Selinexor will be administered orally.

  • DexamethasoneDrug

    Dexamethasone will be administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Clinical Research Center for Blood Diseases

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.